Johns Hopkins researchers developed an experimental drug, NLY01, that blocked the degradation of brain cells, the hallmark of Parkinson’s disease, in cultures of human brain cells, and stopped or slowed disease and symptom progression in live mouse models, as reported in Nature Medicine.

See the source article by following the link below:
Johns Hopkins researchers developed an experimental drug, NLY01, that blocked the degradation of brain cells, the hallmark of Parkinson’s disease, in cultures of human brain cells, and stopped or slowed disease and symptom progression in live mouse models, as reported in Nature Medicine.